Literature DB >> 8256969

Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease. A prospective comparison study.

D B Mark1, L C Lam, K L Lee, R H Jones, D B Pryor, R S Stack, R B Williams, N E Clapp-Channing, R M Califf, M A Hlatky.   

Abstract

OBJECTIVE: To compare return-to-work rates after coronary angioplasty, coronary bypass surgery, and medical therapy in patients with coronary disease.
DESIGN: Prospective cohort study.
SETTING: Tertiary care referral center. PATIENTS: Between March 1986 and June 1990, we enrolled 1252 patients who were younger than 65 years, who had not had previous coronary revascularization, and who were employed. All patients were followed for 1 year. MAIN OUTCOME MEASURE: One-year employment status.
RESULTS: After 1 year, 84% of patients who had coronary angioplasty were still working compared with 79% of patients who had bypass surgery and with 76% of patients who received medicine. After adjusting for the more favorable baseline characteristics of patients who had angioplasty (less severe coronary artery disease, better left ventricular function, and less functional impairment), however, no significant differences were noted in 1-year employment rates among the three groups. These adjusted 1-year return-to-work rates were 84% for angioplasty, 80% for surgery, and 79% for medicine (P > 0.05). In a random subset of 72 patients, 23 patients who had angioplasty returned to work after a median of 18 days (mean, 27 days) compared with 54 days (mean, 67 days) for 24 patients having bypass surgery and with 14 days (mean, 45 days) for 25 patients receiving medicine (P = 0.002).
CONCLUSIONS: Patients who had coronary angioplasty were able to return to work earlier than those who had bypass surgery, but by 1 year no significant difference was noted in employment rates. Neither revascularization strategy improved employment rates when compared with initial treatment using medical therapy.

Entities:  

Mesh:

Year:  1994        PMID: 8256969     DOI: 10.7326/0003-4819-120-2-199401150-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Psychosocial Working Environment and Risk of Adverse Cardiac Events in Patients Treated for Coronary Heart Disease.

Authors:  Karin Biering; Johan Hviid Andersen; Thomas Lund; Niels Henrik Hjollund
Journal:  J Occup Rehabil       Date:  2015-12

2.  The Angina-related Limitations at Work Questionnaire.

Authors:  D J Lerner; B C Amick; S Malspeis; W H Rogers; D R Gomes; D N Salem
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

3.  Effect of Psychosocial Work Environment on Sickness Absence Among Patients Treated for Ischemic Heart Disease.

Authors:  Karin Biering; Thomas Lund; Johan Hviid Andersen; Niels Henrik Hjollund
Journal:  J Occup Rehabil       Date:  2015-12

4.  The Bypassing the Blues treatment protocol: stepped collaborative care for treating post-CABG depression.

Authors:  Bruce L Rollman; Bea Herbeck Belnap; Michelle S LeMenager; Sati Mazumdar; Herbert C Schulberg; Charles F Reynolds
Journal:  Psychosom Med       Date:  2009-02-02       Impact factor: 4.312

5.  Sickness absence following coronary revascularisation. A national study of women and men of working age in Sweden 1994-2006.

Authors:  Margaretha Voss; Torbjörn Ivert; Kenneth Pehrsson; Niklas Hammar; Kristina Alexanderson; Tage Nilsson; Marjan Vaez
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

6.  Return to work after percutaneous coronary intervention: the predictive value of self-reported health compared to clinical measures.

Authors:  Karin Biering; Torsten Toftegaard Nielsen; Kurt Rasmussen; Troels Niemann; Niels Henrik Hjollund
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

7.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada.

Authors:  Judith A O'Brien; Amanda R Patrick; J Jaime Caro
Journal:  BMC Health Serv Res       Date:  2003-03-21       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.